Patents Examined by Valarie Bertoglio
  • Methods for mitochondrial DNA replacement in oocytes
    Patent number: 9434921
    Abstract: Methods are provided for producing a primate oocyte in vitro. The methods include removing nuclear DNA from a recipient primate oocyte from a first primate in a manner that does not lower levels of maturation promoting factor (MPF) to form an enucleated recipient primate oocyte. The recipient primate oocyte is enucleated using a non-UV-based spindle imaging system. Nuclear genetic material or DNA including chromosomes from a donor primate oocyte arrested at metaphase II from a second primate is isolated in the form of the karyoplast and introduced into the enucleated recipient primate oocyte. Introduction of the chromosomes is performed using a fusogenic agent or electroporation to produce a hybrid oocyte.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: September 6, 2016
    Assignee: Oregon Health & Science University
    Inventor: Shoukhrat M. Mitalipov
  • Methods of modulating thrombocytopenia and modified transgenic pigs
    Patent number: 9420770
    Abstract: The application provides methods of modulating platelet uptake by liver sinusoidal endothelial cells and of modulating thrombocytopenia. Transgenic pigs modified to bind fewer platelets are provided.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: August 23, 2016
    Assignee: INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION
    Inventors: Alfred Joseph Tector, III, Christopher Burlak
  • Hepatocyte-like cells and uses thereof
    Patent number: 9416348
    Abstract: The present invention relates to hepatocyte-like cells. Also disclosed are methods of making the cells and using the cells.
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: August 16, 2016
    Assignees: Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences
    Inventors: Lijian Hui, Pengyu Huang, Xin Wang
  • Directed evolution and in vitro panning of virus vectors
    Patent number: 9402921
    Abstract: The present invention provides methods of achieving directed evolution of viruses by in vivo screening or “panning” to identify viruses comprising scrambled AAV capsids having characteristics of interest, e.g., tropism profile and/or neutralization profile (e.g., ability to evade neutralizing antibodies). The invention also provides scrambled AAV capsids and virus particles comprising the same.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: August 2, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Xiao Xiao, Lin Yang
  • Humanized IL-6 and IL-6 receptor
    Patent number: 9392777
    Abstract: Mice that comprise a replacement of endogenous mouse IL-6 and/or IL-6 receptor genes are described, and methods for making and using the mice. Mice comprising a replacement at an endogenous IL-6R? locus of mouse ectodomain-encoding sequence with human ectodomain-encoding sequence is provided. Mice comprising a human IL-6 gene under control of mouse IL-6 regulatory elements is also provided, including mice that have a replacement of mouse IL-6-encoding sequence with human IL-6-encoding sequence at an endogenous mouse IL-6 locus.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: July 19, 2016
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Li-Hsien Wang, Anthony T. Dore, Jr., Sean Stevens, Andrew J. Murphy
  • Compositions and methods for reprogramming eukaryotic cells
    Patent number: 9371544
    Abstract: The present invention relates to methods for changing the state of differentiation of a eukaryotic cell, the methods comprising introducing mRNA encoding one or more reprogramming factors into a cell and maintaining the cell under conditions wherein the cell is viable and the mRNA that is introduced into the cell is expressed in sufficient amount and for sufficient time to generate a cell that exhibits a changed state of differentiation compared to the cell into which the mRNA was introduced, and compositions therefor. For example, the present invention provides mRNA molecules and methods for their use to reprogram human somatic cells into pluripotent stem cells.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: June 21, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • RNA preparations comprising purified modified RNA for reprogramming cells
    Patent number: 9371511
    Abstract: The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 21, 2016
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Katalin Kariko, Drew Weissman, Gary Dahl, Anthony Person, Judith Meis, Jerome Jendrisak
  • Transformed human pluripotent stem cells and associated methods
    Patent number: 9365821
    Abstract: The present disclosure provides transformed human pluripotent stem cell (t-hPSC). t-hPSCs are not dependent on Oct4 for renewal and survival, however exhibit a sensitivity to reduced levels of the transcription factor Nanog. Also provided are methods of culturing cells for use in a cell-based screening assay comprising placing one or more transformed human pluripotent stem cells into a receptacle and culturing said stem cells in the receptacle to form a monolayer of stem cells without cell overlap. Methods of screening compounds using t-hPSCs are also described.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: June 14, 2016
    Assignee: MCMASTER UNIVERSITY
    Inventors: Mickie Bhatia, Tamra Werbowetski-Ogilvie, Eleftherios Sachlos, Daniela Fischer Russell, Sarah Laronde, JungBok Lee, Eva Szabo, Ruth Risueno
  • Genetically modified muscle cells which express neurotrophic factors
    Patent number: 9365828
    Abstract: An isolated muscle progenitor cell being MyoD positive, CD34 negative and CD45 negative is disclosed. The muscle progenitor cell is genetically modified to express at least one neurotrophic factor. In addition, cell populations are disclosed, comprising at least four subpopulations of muscle cells each being genetically modified to express a different neurotrophic factor, wherein said neurotrophic factor is selected from the group consisting of glial derived neurotrophic factor (GDNF), insulin growth factor (IGF-1), vascular endothelial growth factor (VEGF) and brain-derived neurotrophic factor (BDNF). Uses of the cell populations are also disclosed.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: June 14, 2016
    Assignees: Ramot at Tel-Aviv University Ltd., Yeda Research and Development Co., Ltd.
    Inventors: Daniel Offen, Michal Dadon-Nachum, Tali Ben-Zur, Eldad Melamed, David Yaffe
  • Method of preparing cells susceptible to transmissible spongiform encephalopathy and the creation of TSE persistently infected cells
    Patent number: 9359595
    Abstract: Disclosed is a method for preparation of transmissible spongiform encephalopathy (TSE) susceptible cells, and such cells may be efficiently used in diagnosis of TSE, etiology studies and development of novel therapeutics, etc.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: June 7, 2016
    Assignee: Animal, Plant and Fisheries Quarantine and Inspection Agency
    Inventors: Dong-Seob Tark, Hyo-Jin Kim, Hyun-Joo Shon, Yoon-Hee Lee, Min-Jeong Kim, Eun-Im Yun, In-Soo Cho, Chang-Hee Kweon, Yi-Seok Joo, Otto Windl, Michael Neale
  • Tissue-derived tissuegenic implants, and methods of fabricating and using same
    Patent number: 9352003
    Abstract: The disclosure provides implants containing a plurality of particles containing at least one population of viable osteogenic cells adherent to and resident in an osteoconductive matrix or at least one viable population of osteogenic cells caused to be in contact with the osteoconductive matrix; methods of fabricating the implants; and use of the implants in bone repair. The implant further contains an osteoinductive component. An example of an osteoinductive component is a demineralized bone matrix in the form of particles or fibers.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: May 31, 2016
    Assignee: MUSCULOSKELETAL TRANSPLANT FOUNDATION
    Inventors: Eric Semler, Alex Callahan, Joed Canales, Katrina Carroll, Anouska Dasgupta, Roman Shikanovich
  • Reprogramming T cells and hematopoietic cells
    Patent number: 9347044
    Abstract: Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from CD34+ hematopoietic cells, such as human CD34+ blood progenitor cells, or T cells. Various iPS cell lines are also provided. In certain embodiments, the invention provides novel induced pluripotent stem cells with a genome comprising genetic rearrangement of T cell receptors.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: May 24, 2016
    Assignee: Cellular Dynamics International, Inc.
    Inventors: Matthew Brown, Elizabeth Rondon Dominguez, Randy Learish, Emile Nuwaysir, Deepika Rajesh, Amanda Mack
  • Multi-transgenic pigs for diabetes treatment
    Patent number: 9339519
    Abstract: The present invention provides certain animals, and in particular porcine animals, tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (?GT) and express one or more additional transgenes which make them suitable donors for pancreatic islet xenotransplantation. Methods of treatment and prevention of diabetes using cells derived from such animals are also provided.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: May 17, 2016
    Assignee: Revivicor, Inc.
    Inventor: David Ayares
  • Method for screening agent with angiogenic-modulating activities using teleost embryo
    Patent number: 9335321
    Abstract: This invention relates to a method of 3-tier system for screening compounds, herb extract or extract of herb combination in formula with angiogenic-modulating activities using transparent teleost embryos as model.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: May 10, 2016
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventors: Shuk Han Cheng, Po Kwok Chan
  • Cellular extracts
    Patent number: 9314488
    Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. The agents include compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.
    Type: Grant
    Filed: October 29, 2014
    Date of Patent: April 19, 2016
    Assignee: REGENICS AS
    Inventors: Runhild Gammelsaeter, Jan Remmereit
  • Neural stem cells
    Patent number: 9309495
    Abstract: A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.
    Type: Grant
    Filed: July 21, 2014
    Date of Patent: April 12, 2016
    Assignee: The University Court of The University of Edinburgh
    Inventors: Luciano Conti, Steven Michael Pollard, Austin Gerard Smith
  • Recombinant constructs and transgenic fluorescent ornamental fish therefrom
    Patent number: 9295237
    Abstract: The present invention relates to the method and use of reef coral fluorescent proteins in making transgenic red, green and yellow fluorescent zebrafish. Preferably, such fluorescent zebrafish are fertile and used to establish a population of transgenic zebrafish and to provide to the ornamental fish industry for the purpose of marketing. Thus, new varieties of ornamental fish of different fluorescence colors from a novel source are developed.
    Type: Grant
    Filed: October 12, 2009
    Date of Patent: March 29, 2016
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Jeffrey Essner, Perry Hackett, Aidas Nasevicius
  • Pink transgenic fluorescent ornamental fish
    Patent number: 9295238
    Abstract: The present invention relates to transgenic pink ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 29, 2016
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius
  • Methods of identifying xenohormetic phenotypes and agents
    Patent number: 9291615
    Abstract: Methods of identifying a xenohormetic induced phenotype in an organism are provided. Also provided are methods if using organisms having a known xenohormetically induced phenotype in a number of different applications, such as the identification of xenohormetic agents and the generation of chemical entities and foodstuffs under specific conditions of production governed by xenohormetic effects.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: March 22, 2016
    Assignee: Palo Alto Investors
    Inventor: Anthony Joonkyoo Yun
  • Purple transgenic fluorescent ornamental fish
    Patent number: 9282729
    Abstract: The present invention relates to transgenic purple ornamental fish, as well as methods of making such fish by in vitro fertilization techniques. Also disclosed are methods of establishing a population of such transgenic fish and methods of providing them to the ornamental fish industry for the purpose of marketing.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: March 15, 2016
    Assignee: Yorktown Technologies, L.P.
    Inventors: Alan Blake, Richard Crockett, Aidas Nasevicius